Avalo Therapeutics News - AVTX

Company Name	Stock Ticker Symbol	Market	Type
Avalo Therapeutics Inc	AVTX	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	-0.26	-2.16%	11.75	16:00:10

Open Price	Low Price	High Price	Close Price	Prev Close
11.68	11.5001	13.0199	11.75	12.01

more quote information »

Recent News

Date	Time	Source	Heading
4/02/2024	07:00	GLOBE	Avalo Therapeutics Appoints Biotech Leaders to Board of..
3/29/2024	16:01	GLOBE	Avalo Reports 2023 Financial Results and Provides Business..
3/27/2024	16:01	GLOBE	Avalo Acquires Anti-IL-1β mAb and Announces Private..
2/14/2024	21:13	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
2/14/2024	10:02	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
1/31/2024	16:01	EDGAR2	Form 8-K - Current report
12/28/2023	17:05	EDGAR2	Form 8-K - Current report
12/27/2023	07:00	GLOBE	Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
12/21/2023	16:05	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/21/2023	16:01	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
12/20/2023	16:01	EDGAR2	Form 8-K - Current report
12/07/2023	07:02	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
12/07/2023	07:01	EDGAR2	Form 8-K - Current report
12/07/2023	07:00	GLOBE	Avalo Encourages Stockholders to Vote FOR the Reverse Stock..
11/16/2023	07:15	EDGAR2	Form 8-K - Current report
11/09/2023	07:21	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/09/2023	07:04	EDGAR2	Form 8-K - Current report
11/09/2023	07:00	GLOBE	Avalo Reports Third Quarter 2023 Financial Results and..
10/31/2023	07:21	EDGAR2	Form 8-K - Current report
10/31/2023	07:00	GLOBE	Avalo Completes Divestiture of AVTX-800 Series
10/19/2023	16:15	EDGAR2	Form ARS - Annual Report to Security Holders
10/19/2023	16:06	EDGAR2	Form DEFA14A - Additional definitive proxy soliciting..
10/19/2023	16:01	EDGAR2	Form DEF 14A - Other definitive proxy statements
10/17/2023	16:02	EDGAR2	Form 8-K - Current report
10/05/2023	16:02	EDGAR2	Form PRE 14A - Other preliminary proxy statements
9/26/2023	07:04	EDGAR2	Form 8-K - Current report
9/26/2023	07:00	GLOBE	Avalo Therapeutics Successfully Eliminates $35 Million Debt..
9/13/2023	16:03	EDGAR2	Form 8-K - Current report
9/13/2023	09:12	EDGAR2	Form 8-K - Current report
9/12/2023	07:10	EDGAR2	Form 8-K - Current report
9/12/2023	07:00	GLOBE	Avalo Enters into Agreement to Divest AVTX-800 Series
9/11/2023	07:22	EDGAR2	Form 8-K - Current report
9/06/2023	07:00	GLOBE	Avalo to Present at the H.C. Wainwright 25th Annual Global..
8/14/2023	16:23	EDGAR2	Form 8-K - Current report
8/08/2023	16:11	EDGAR2	Form 8-K - Current report
8/07/2023	17:27	EDGAR2	Form 8-K - Current report
8/07/2023	17:26	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
8/03/2023	07:03	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/03/2023	07:01	EDGAR2	Form 8-K - Current report
8/03/2023	07:00	GLOBE	Avalo Reports Second Quarter 2023 Financial Results and..
7/21/2023	08:25	EDGAR2	Form 8-K - Current report
7/06/2023	16:01	GLOBE	Avalo to Participate in SVB Securities Therapeutics Forum
6/29/2023	08:22	EDGAR2	Form SC 13G/A - Statement of acquisition of beneficial..
6/28/2023	18:12	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
6/26/2023	07:00	GLOBE	Avalo Announces Topline Data from Phase 2 PEAK Trial for..
6/01/2023	07:00	GLOBE	Avalo to Present at the Jefferies Healthcare Conference
5/22/2023	07:00	GLOBE	Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff..
5/15/2023	07:00	GLOBE	Avalo to Present at ATS 2023 Respiratory Innovation Summit
5/10/2023	07:00	GLOBE	Avalo to Present at the 2023 RBC Capital Markets Global..
5/04/2023	16:01	GLOBE	Avalo Reports First Quarter 2023 Financial Results and..